In those with advanced CF lung disease (n=14), 3 months of ETI treatment reduced plasma IL-6 levels alongside associated reductions in the acute phase proteins C-reactive protein and α1 anti-trypsin, changes that were also apparent at 1 year [40]. This evidence concerns the gene IL6 and cystic fibrosis.